Article Figures & Data
Figures
- Figure 1
- (A) Flow diagram of the study. (B) The number of patients with different Naples prognostic scores (NPSs) before and after neoadjuvant chemoradiotherapy. (C) Kaplan–Meier curves for overall survival (OS) in the elevated NPS and non-elevated NPS groups. (D) Kaplan–Meier curves for recurrence-free survival (RFS) in the elevated NPS and non-elevated NPS groups.
Tables
Grade (Points) Serum albumin (g/dL) Total cholesterol (mg/dL) NLR LMR 0 ≥4.0 >180 ≤2.96 >4.44 1 <4.0 ≤180 >2.96 ≤4.44 LMR: lymphocyte-to-monocyte ratio, NLR: neutrophil-to-lymphocyte ratio
Variables Elevated NPS group (n=105) Non-elevated NPS group (n=127) P-value n (%) n (%) Age (year), median (±SD) 61.6 ± 7.5 62.1 ± 7.7 0.606 BMI, median (±SD) Before NAT 22.6 ± 3.2 22.3 ± 2.9 0.414 Before surgery 22.5 ± 3.3 22.5 ± 3.0 0.947 Gender 0.125 Male 84 (80.0) 111 (87.4) Female 21(20.0) 16 (12.6) Tumor type NA SCC 105 (100) 127 (100) Tumor location 0.458 Upper 12 (11.4) 9 (7.1) Middle 66 (62.9) 80 (63.0) Lower 27 (25.7) 38 (29.9) Tumor length 0.819 >3 cm 27 (25.7) 31 (24.4) ≤3 cm 78 (74.3) 96 (75.6) ypTNM stage 0.864 I 59 (56.2) 68 (53.5) II 12 (11.4) 17 (13.4) III 29 (27.6) 38 (29.9) IV 5 (4.8) 4 (3.1) cTNM stage 0.211 II 19 (18.1) 13 (10.2) III 66 (62.9) 85 (66.9) IV 20 (19.0) 29 (22.8) Tumor regression score 0.386 0 46 (43.8) 53 (41.7) 1 12 (11.4) 23 (18.1) 2 42 (40.0) 42* (33.1) 3 5 (4.8) 9 (7.1) pCR 41 (39.0) 50 (39.4) 0.960 Number of days in hospital, median (IQR), days 15 (13-17) 14 (13-15) 0.671 Time between NACR and surgery, median (IQR), days 70 (63-81) 68 (60-87) 0.230 BMI: body mass index, IQR: interquartile range, LOS: length of stay, NAT: neoadjuvant therapy, pCR: pathological complete regression, SD: standard deviation, SCC: Squamous cell carcinoma
- Table 3
- Univariate and multivariate analyses of clinicopathological factors linked to overall survival
Variables Univariate analysis Multivariate analysis HR (95% CI) P-value HR (95% CI) P-value Change in NPS after NACR Elevated NPS group versus non-elevated NPS group 1.631(1.061-2.507) 0.026 1.868 (1.063-2.646) 0.036 Pre-NACR NPS ≥3 versus <3 0.940 (0.589-1.501) 0.796 Post-NACR NPS ≥3 versus <3 1.750 (1.140-2.687) 0.010 1.072 (0.622-1.848) 0.803 Pre-NACR serum albumin (g/dL) <4 versus ≥4 1.088(0.658-1.797) 0.742 Pre-NACR total cholesterol (mg/dL) ≤180 versus >180 1.010(0.657-1.533) 0.963 Pre-NACR NLR >2.96 versus ≤2.96 0.806(0.505-1.287) 0.366 Pre-NACR LMR ≤4.44 versus <4.44 1.057(0.639-1.746) 0.830 Post-NACR serum albumin (g/dL) <4 versus ≥4 1.154(0.858-1.897) 0.527 Post-NACR total cholesterol (mg/dL) ≤180 versus >180 1.284(0.837-1.804) 0.253 Post-NACR NLR >2.96 versus ≤2.96 1.162(0.749-1.84) 0.502 Post-NACR LMR ≤4.44 versus <4.44 0.541(0.171-1.715) 0.497 Age (year) ≥60 versus <60 1.093 (0.700-1.708) 0.696 Gender Male versus female 1.962 (0.947-4.067) 0.07 Tumor length >3 cm versus ≤3 cm 1.861 (1.190-2.910) 0.006 1.636 (1.013-2.641) 0.044 BMI (kg/m2) Before NAT (≤22 versus >22) 1.483 (0.966-2.277) 0.072 Before surgery (≤22 versus >22) 1.439 (0.938-2.208) 0.096 Tumor location Ut versus Mt/Lt 1.034 (0.499-2.144) 0.927 ypTNM stage III-IV versus I-II 4.127 (2.666-6.391) <0.001 3.89 (2.475-6.115) <0.001 cTNM stage III-IV versus II 1.010 (0.547-1.867) 0.974 HR: hazard ratio, LMR: lymphocyte-to-monocyte ratio, NPS: naples prognostic score, NACR: neoadjuvant chemoradiotherapy, NLR: neutrophil-to-lymphocyte ratio, CI: confidence interval
- Table 4
- Univariate and multivariate analyses of clinicopathological factors linked to recurrence-free survival
Variables Univariate analysis Multivariate analysis P value HR (95% CI) P-value HR (95% CI) Change in NPS after NACR Elevated NPS group versus non-elevated NPS group 1.497 (1.002-2.235) 0.049 1.709 (1.291-2.854) 0.029 Pre-NACR NPS ≥3 versus <3 0.855 (0.548-1.334) 0.490 Post-NACR NPS ≥3 versus <3 1.475 (0.986-2.205) 0.058 Pre-NACR serum albumin (g/dL) <4 versus ≥4 1.121(0.702-1.792) 0.632 Pre-NACR total cholesterol (mg/dL) ≤180 versus >180 0.980(0.656-1.464) 0.920 Pre-NACR NLR >2.96 versus ≤2.96 0.892(0.579-1.374) 0.605 Pre-NACR LMR ≤4.44 versus <4.44 0.932(0.587-1.479) 0.764 Post-NACR serum albumin (g/dL) <4 versus ≥4 1.038(0.655-1.589) 0.720 Post-NACR total cholesterol (mg/dL) ≤180 versus >180 1.055(0.707-1.575) 0.793 Post-NACR NLR >2.96 versus ≤2.96 1.102(0.732-1.659) 0.641 Post-NACR LMR ≤4.44 versus <4.44 0.615(0.195-1.943) 0.408 Age (year) ≥60 versus >60 0.929 (0.616-1.402) 0.726 Gender Male versus female 1.582 (0.844-2.965) 0.153 Tumor length >3 cm versus ≤3 cm 2.016 (1.326-3.064) 0.001 1.96 (1.247-3.08) 0.004 BMI (kg/m2) Before NAT (≤22 versus >22) 1.406 (0.941-2.099) 0.096 Before surgery (≤22 versus >22) 1.452 (0.973-2.166) 0.068 Tumour location Ut versus Mt/Lt 1.052 (0.530-2.090) 0.885 ypTNM stage III-IV versus I-II 3.529 (2.351-5.298) 0<0.001 3.361 (2.2-5.135) <0.001 cTNM stage III-IV versus II 1.200 (0.654-2.200) 0.556 HR: hazard ratio, LMR: lymphocyte-to-monocyte ratio, NPS: naples prognostic score, NACR: neoadjuvant chemoradiotherapy, NLR: neutrophil-to-lymphocyte ratio
- Table 5
- Morbidity and mortality in elevated Naples prognostic score (NPS) and non-elevated NPS groups.
Variables Elevated NPS group (n=105) Non-elevated NPS group (n=127) P-value n (%) n (%) Anastomotic leakage 8 (7.6) 7 (5.5) 0.516 Anastomotic stricture (CD grade 2) 6 (5.7) 1 (0.8) 0.029 Vocal cord injury (CD type 1) 9 (8.5) 10 (7.8) 0.811 Pneumonia 30 (28.6) 34 (26.8) 0.212 Respiratory failure (CD grades 3–4) 3 (2.9) 3 (2.4) 0.813 Cardiac complications (CD grades 1–2) 1 (1.0) 3 (2.4) 0.412 ICU stay 7 (6.7) 6 (4.7) 0.789 Clavien–Dindo grade CD I–II 17 (16.2) 12 (9.5) 0.122 CD III–V 10 (9.5) 12 (9.5) 0.985 Postoperative LOS, median (IQR), days 11 (9-13) 10 (9-12) 0.528 30-Day mortality 3 (2.9) 1 (0.8) 0.228 30-Day readmissions 2 (1.9) 1 (0.8) 0.528 CD: Clavien–Dindo classification system, ICU: intensive care unit, IQR: interquartile range, LOS: length of stay
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.